U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8O2
Molecular Weight 136.1479
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLACETIC ACID

SMILES

OC(=O)CC1=CC=CC=C1

InChI

InChIKey=WLJVXDMOQOGPHL-UHFFFAOYSA-N
InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C8H8O2
Molecular Weight 136.1479
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://clinicaltrials.gov/ct2/show/NCT00003241?term=Phenylacetic+acid&rank=3 https://en.wikipedia.org/wiki/Phenylacetic_acid

Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.

CNS Activity

Curator's Comment: Known to be CNS penetrant in cat. Human data not available. Labeled phenylacetic acid (14C-PAA) penetrates blood-cerebrospinal fluid (CSF) barrier in cats only under a high gradient of concentration

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMMONUL

Approved Use

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.

Launch Date

1.10851195E12
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2225 μM
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3022 μM
5.5 g/m² single, intravenous
dose: 5.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
281 μM
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETYLGLUTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15004 μM × h
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
28156 μM × h
5.5 g/m² single, intravenous
dose: 5.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2047 μM × h
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETYLGLUTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.44%
SODIUM PHENYLACETATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Disc. AE: Metabolic acidosis, Injection site reactions...
AEs leading to
discontinuation/dose reduction:
Metabolic acidosis (< 1%)
Injection site reactions (< 1%)
Bradycardia (0.32%)
Abdominal distension (0.32%)
Injection site extravasation (0.32%)
Hemorrhage injection site (0.32%)
Blister (0.32%)
Subdural hematoma (0.32%)
Hyperammonemia (0.32%)
Hypoglycemia (0.32%)
Clonus (0.32%)
Coma (0.32%)
Increased intracranial pressure (0.32%)
Hypercapnia (0.32%)
Kussmaul respiration (0.32%)
Respiratory distress (0.32%)
Respiratory failure (0.32%)
Pruritis (0.32%)
Maculo-papular rash (0.32%)
Sources: Page: p.11
300 mg/kg 1 times / day multiple, intravenous (max)
Recommended
Dose: 300 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Cancer
Sources: Page: p.8
Other AEs: Neurotoxicity...
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Blister 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Bradycardia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Clonus 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Coma 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hemorrhage injection site 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hyperammonemia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hypercapnia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hypoglycemia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Increased intracranial pressure 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Injection site extravasation 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Kussmaul respiration 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Maculo-papular rash 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Pruritis 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Respiratory distress 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Respiratory failure 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Subdural hematoma 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Injection site reactions < 1%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Metabolic acidosis < 1%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Neurotoxicity
300 mg/kg 1 times / day multiple, intravenous (max)
Recommended
Dose: 300 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Cancer
Sources: Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Penicillin productivity and glutathione-dependent detoxification of phenylacetic and phenoxyacetic acids in Penicillium chrysogenum.
2001
Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors.
2001 Apr 1
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
2001 Aug
New bitter-tasting hemiterpene glycosides from the Japanese fern Hymenophyllum barbatum.
2001 Dec
Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
2001 Dec
Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer.
2001 Dec
Suppression of tumourigenicity, and induction of differentiation of the canine mammary tumour cell line MCM-B2 by sodium phenylacetate.
2001 Feb
Expression and purification of extracellular penicillin G acylase in Bacillus subtilis.
2001 Feb
[Determination of degraded products of penicillin by high performance liquid chromatography].
2001 Jan
Alternative pathway therapy for urea cycle disorders: twenty years later.
2001 Jan
The phenylacetyl-CoA catabolon: a complex catabolic unit with broad biotechnological applications.
2001 Mar
Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
2001 Mar
Expression of penicillin G acylase from the cloned pac gene of Escherichia coli ATCC11105. Effects of pacR and temperature.
2001 Mar
Could 99mTc-MIBI be used to visualize the apoptotic MCF7 human breast cancer cells?
2001 May
Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate.
2001 May
Quantum molecular similarity. 3. QTMS descriptors.
2001 May-Jun
Trifluoromethyl ketone-based inhibitors of apoptosis in cerebellar granule neurons.
2001 Nov
The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification.
2001 Nov
Quantitative gas chromatography-olfactometry carried out at different dilutions of an extract. Key differences in the odor profiles of four high-quality Spanish aged red wines.
2001 Oct
Oxygen dependency of monoamine oxidase activity in the intact lung.
2001 Oct
Inhibition of estrogen-dependent breast cell responses with phenylacetate.
2001 Sep 1
Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice.
2001 Sep 14
Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects.
2001 Sep-Oct
The role of hydrophobic active-site residues in substrate specificity and acyl transfer activity of penicillin acylase.
2002 Apr
New glycosides from the Japanese fern Hymenophyllum barbatum.
2002 Apr
Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo.
2002 Apr
Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids.
2002 Feb
[Penicillin G acylase--synthesis, regulation, production].
2002 Jan
Polarization IR spectra of the hydrogen bond in phenylacetic acid crystals: H/D isotopic effects temperature and polarization effects.
2002 Jul
Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry.
2002 Jul 1
Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans.
2002 Jun
Induction and repression of the sty operon in Pseudomonas putida CA-3 during growth on phenylacetic acid under organic and inorganic nutrient-limiting continuous culture conditions.
2002 Mar 5
Characterization of tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype.
2002 May-Jun
Arginine 165/arginine 277 pair in (S)-mandelate dehydrogenase from Pseudomonas putida: role in catalysis and substrate binding.
2002 Oct 15
Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy.
2002 Sep
[Treatment of methicillin-resistant Staphylococcus aureus (MRSA) as part of biosurgical management of a chronic leg ulcer].
2002 Sep
Aerobic metabolism of phenylacetic acids in Azoarcus evansii.
2002 Sep
Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep.
2003 Feb
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
2003 Feb 10
Environmental effects caused by olive mill wastewaters: toxicity comparison of low-molecular-weight phenol components.
2003 Feb 12
Dual stereoselectivity of 1-(2'-carboxy)benzyl 2-deoxyglycosides as glycosyl donors in the direct construction of 2-deoxyglycosyl linkages.
2003 Jan 27
Patents

Sample Use Guides

Unknown
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:49:26 UTC 2023
Edited
by admin
on Wed Jul 05 22:49:26 UTC 2023
Record UNII
ER5I1W795A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYLACETIC ACID
FCC   FHFI   MI  
Systematic Name English
PHENYLACETIC ACID [MI]
Common Name English
TROPICAMIDE IMPURITY D [EP IMPURITY]
Common Name English
PHENYLACETIC ACID [HSDB]
Common Name English
NSC-125718
Code English
.ALPHA.-TOLUIC ACID
Systematic Name English
FEMA NO. 2878
Code English
BENZYLPENICILLIN (BENZATHINE) TETRAHYDRATE IMPURITY B { EP IMPURITY]
Common Name English
PROCAINE BENZYLPENICILLIN IMPURITY E [EP IMPURITY]
Common Name English
.OMEGA.-PHENYLACETIC ACID
Common Name English
PHENYLACETIC ACID [FCC]
Common Name English
BENZYLPENICILLIN SODIUM IMPURITY B [EP IMPURITY]
Common Name English
TROPICAMIDE RELATED COMPOUND D [USP IMPURITY]
Common Name English
ACETIC ACID, PHENYL-
Systematic Name English
2-PHENYLACETIC ACID
Systematic Name English
BENZYLPENICILLIN POTASSIUM IMPURITY B [EP IMPURITY]
Common Name English
ASTUGENAL COMPONENT PHENYLACETIC ACID
Common Name English
PHENYLACETIC ACID [FHFI]
Common Name English
TROPICAMIDE RELATED COMPOUND D [USP-RS]
Common Name English
ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
Common Name English
ANTINEOPLASTON AS 2-1 COMPONENT PHENYLACETIC ACID
Common Name English
Classification Tree Code System Code
CFR 21 CFR 172.515
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
DEA NO. 8791
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
NDF-RT N0000175807
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
FDA ORPHAN DRUG 267408
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
NDF-RT N0000175806
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
JECFA EVALUATION PHENYLACETIC ACID
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
DEA NO. 8791
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
FDA ORPHAN DRUG 189804
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C77487
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
HSDB
5010
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
WIKIPEDIA
PHENYLACETIC ACID
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
SMS_ID
100000172583
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
MESH
C025136
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
RS_ITEM_NUM
1699049
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
CAS
103-82-2
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
DRUG BANK
DB09269
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
DAILYMED
ER5I1W795A
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
CHEBI
30745
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
ECHA (EC/EINECS)
203-148-6
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
PUBCHEM
999
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
NCI_THESAURUS
C45678
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
CONCEPT Industrial Aid
FDA UNII
ER5I1W795A
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
DRUG CENTRAL
4624
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID2021656
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
RXCUI
33332
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C1613
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
ALTERNATIVE
MERCK INDEX
M8650
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY Merck Index
NSC
125718
Created by admin on Wed Jul 05 22:49:26 UTC 2023 , Edited by admin on Wed Jul 05 22:49:26 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT->PRECURSOR
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
The active molecule that combines with glutamine (an amino acid with two nitrogen molecules) to form phenylacetylglutamine which is rapidly excreted by the kidneys and does not require metabolism via the urea cycle. Phenylbutyrate thus provides an “ammonia sink”, an alternative pathway for excretion of excess nitrogen and ammonia. The active metabolite phenylacetate is also effective therapeutically, but has a disagreeable odor and taste that affect compliance and acceptability.
PARENT -> METABOLITE
PARENT -> METABOLITE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
impurity D at 210 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY